Table 1.
ᅟSummary of included publications
| A. The addition of an anti-EGFR mAb to the first-line treatment of mCRC | |||||
| Study (author) | Combination (no. pt) | Control (no. pt) | Response rate % (OR, CI, p) | Median PFS (months) (HR, CI, p) | Median OS (months) (HR, CI, p) |
| OPUS (Bokemeyer) | Cetux + FOLFOX4 (82) | FOLFOX4 (97) | 57 versus 34 (2.6, 1.4–4.7, 0.003) | 8.3 versus 7.2 (0.57, 0.4–0.9, 0.006) | 22.8 versus 18.5 (0.894, 0.6–1.2, 0.56) |
| CRYSTAL (v Cutsem) | Cetux + FOLFIRI (316) | FOLFIRI (350) | 57 versus 40 (2.1, 1.5–2.8, <0.001) | 9.9 versus 8.4 (0.7, 0.6–0.9, 0.001) | 23.5 versus 20.0 (0.8, 0. 7–1.0, 0.009) |
| NORDIC-VII (Tveit) | Cetux + Nordic FLOX (97) | Nordic FLOX (97) | – | 7.9 versus 8.7 (1.07, 0.8–1.5, 0.66) | 20.1 versus 22.0 (1.14, 0.8–1.61, 0.48) |
| – (Ye) | Cetux + FOLFIRI or mFOLFOX6 (70) | FOLFIRI or mFOLFOX6 (86) | 57 versus 29 (2.1, 1.1–4.1, 0.02) | 10.2 versus 5.8 (0.6, 0.4–0.9, 0.004) | 30.9 versus 21.0 (0.54, 0.3–0.9, 0.013) |
| MRC COIN (Maughan) | Cetux + FOLFOX/CAPOX (362) | FOLFOX/CAPOX (367) | 64 versus 57 (1.4, 1.0–1.8, 0.049) | 8.6 versus 8.6 (0.96, 0.8–1.1, 0.6) | 17.0 versus 17.9 (0.96, 0.8–1.2, 0.67) |
| PRIME (Douillard) | Pani + FOLFOX4 (325) | FOLFOX4 (331) | 57 versus 48 (1.5, 1.1–2.0, 0.02) | 10.0 versus 8.6 (0.8, 0.6–1.0, 0.01) | 23.9 versus 19.7 (0.88, 0.7–1.1, 0.17) |
| B. The addition of an anti-EGFR mAb versus an anti-VEGF mAb to the first-line treatment of mCRC | |||||
| CALGB/SWOG 80405 (Vernook) | Cetux + FOLFOX or FOLFIRI (578) | Beva + (FOLFOX or FOLFIRI) (559) | – | 10.4 versus 10.8 (1.04, 0.9–1.2, 0.55) | 29.9 versus 29.0 (0.92, 0.78–1.09, 0.34) |
| FIRE-3 (Heinemann) | Cetux + FOLFIRI (297) | Beva + FOLFIRI (295) | 62 versus 58 (1.2, 0.9–1.6, 0.18) | 10.0 versus 10.3 (1.06, 0.9–1.3, 0.55) | 28.7 versus 25.0 (0.77, 0.62–0.96, 0.017) |
| PEAK (Schwartsberg) | Pani + mFOLFOX6 (142) | Beva + mFOLFOX6 (143) | 58 versus 54 (1.1, 0.7–1.8, 0.59) | 10.9 versus 10.1 (0.87, 0.7–1.2, 0.35) | 34.2 versus 24.3 (0.62, 0.44–0.89, 0.009) |
| C. The addition of an anti-EGFR mAb to the second-line treatment of mCRC | |||||
| 20,050,181 (Peeters) | Pani + FOLFIRI (303) | FOLFIRI (294) | 36 versus 10 (5.5, 3.3–8.9, <0.001) | 6.7 versus 4.9 (0.82, 0.7–1.0, 0.02) | 14.5 versus 12.5 (0.92, 0.8–1.1, 0.37) |
| PICCOLO (Seymour) | Pani + irinotecan (230) | Irinotecan (230) | 34 versus 12 (4.1, 2.5–6.8, <0.001) | 5.5 versus 4.7 (0.78, 0.6–1.0, 0.02) | 10.4 versus 10.9 (1.01, 0.83–1.23, 0.91) |
| D. The addition of an anti-EGFR mAb to the third-line treatment of mCRC | |||||
| 20,020,408 (Amado) | Pani + BSC (115) | BSC (114) | 17 versus 0 | 3.1 versus 1.8 (0.45, 0.3–0.6, <0.001) | 8.1 versus 7.6 (0.99, 0.8–1.3)a |
| CO.17 (Karapetis) | Cetux +BSC (110) | BSC (105) | 13 versus 0 | 3.7 versus 1.9 (0.4, 0.3–0.5, <0.001) | 9.5 versus 4.8 (0.55, 0.4–0.7, <0.001) |
mAb monoclonal antibodies, mCRC metastatic colorectal cancer, Cetux cetuximab, Pani panitumumab, Beva bevacizumab, BSC best supportive care, OR odds ratio, CI confidence interval, HR hazard ratio, OS overall survival, PFS progression-free survival
aCrossover design